Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer

Table 2 Side effects associated with nab-paclitaxel and oxaliplatin + S-1 and standard S-1 and oxaliplatin treatment, n (%)

Variables	Total (n = 219)	P-SOX (n = 149)	SOX (n = 70)	P value
Fewer neutrophils				0.598
0	168 (77.4)	115 (77.2)	53 (77.9)
1	37 (17.1)	24 (16.1)	13 (19.1)
2	2 (0.9)	1 (0.7)	1 (1.5)
3	6 (2.8)	5 (3.4)	1 (1.5)
4	4 (1.8)	4 (2.7)	0 (0)
Fewer white blood cells				0.418
0	141 (64.4)	95 (63.8)	46 (65.7)
1	50 (22.8)	33 (22.1)	17 (24.3)
2	18 (8.2)	13 (8.7)	5 (7.1)
3	9 (4.1)	8 (5.4)	1 (1.4)
4	1 (0.5)	0 (0)	1 (1.4)
Fewer platelets				0.985
0	158 (72.1)	106 (71.1)	52 (74.3)
1	49 (22.4)	34 (22.8)	15 (21.4)
2	7 (3.2)	5 (3.4)	2 (2.9)
3	5 (2.3)	4 (2.7)	1 (1.4)
Anemia				0.415
0	146 (66.7)	102 (68.5)	44 (62.9)
1	56 (25.6)	35 (23.5)	21 (30)
2	13 (5.9)	8 (5.4)	5 (7.1)
3	4 (1.8)	4 (2.7)	0 (0)
Nausea and vomiting				0.856
0	48 (21.9)	33 (22.1)	15 (21.4)
1	123 (56.2)	81 (54.4)	42 (60)
2	43 (19.6)	31 (20.8)	12 (17.1)
3	5 (2.3)	4 (2.7)	1 (1.4)
Live toxicity				0.057
0	168 (76.7)	113 (75.8)	55 (78.6)
1	40 (18.3)	25 (16.8)	15 (21.4)
2	11 (5)	11 (7.4)	0 (0)
alopecia				0.013
0	82 (37.4)	46 (30.9)	36 (51.4)
1	114 (52.1)	85 (57)	29 (41.4)
2	23 (10.5)	18 (12.1)	5 (7.1)
Peripheral sensory neuropathy				0.052
0	94 (42.9)	58 (38.9)	36 (51.4)
1	87 (39.7)	59 (39.6)	28 (40)
2	35 (16)	30 (20.1)	5 (7.1)
3	3 (1.4)	2 (1.3)	1 (1.4)

PSOX: Nab-paclitaxel and oxaliplatin + S-1; SOX: Standard S-1 and oxaliplatin.